This study will evaluate the changes in glycemic control in overweight and obese adults with
Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of
CT-868 will be compared to placebo. All participants will continue with their standard
diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI).
Alongside their designated treatment, participants will receive guidance on managing their
diabetes, including monitoring blood glucose levels and diet and exercise recommendations.
Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly
determined.